BET Inhibition Modifies Melanoma Infiltrating T Cells and Enhances Response to PD-L1 Blockade

J Invest Dermatol. 2019 Jul;139(7):1612-1615. doi: 10.1016/j.jid.2018.12.024. Epub 2019 Jan 28.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents, Immunological / therapeutic use*
  • CD8-Positive T-Lymphocytes / immunology*
  • Cell Growth Processes / drug effects
  • Cell Line, Tumor
  • Disease Models, Animal
  • Drug Synergism
  • Forkhead Transcription Factors / metabolism
  • Humans
  • Immunotherapy / methods*
  • Lymphocytes, Tumor-Infiltrating / immunology*
  • Melanoma / drug therapy*
  • Mice
  • Nerve Tissue Proteins / antagonists & inhibitors
  • Nerve Tissue Proteins / metabolism*
  • Oxazoles / therapeutic use*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Pyridines / therapeutic use*
  • Pyrroles / therapeutic use*
  • Receptors, Cell Surface / antagonists & inhibitors
  • Receptors, Cell Surface / metabolism*
  • Skin Neoplasms / drug therapy*
  • T-Lymphocytes, Regulatory / immunology*
  • Tumor Burden / drug effects

Substances

  • Antineoplastic Agents, Immunological
  • Dner protein, mouse
  • Forkhead Transcription Factors
  • Foxp3 protein, mouse
  • Nerve Tissue Proteins
  • Oxazoles
  • Pdcd1 protein, mouse
  • Programmed Cell Death 1 Receptor
  • Pyridines
  • Pyrroles
  • Receptors, Cell Surface
  • PLX51107